WALLACE RJ, BROWN-ELLIOTT BA, CRIST CJ, WALLACE RJ; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. E-525.
The University of Texas Health Center, Tyler, TX
BACKGROUND: Although the tetracyclines are useful for treatment of some nontuberculous mycobacteria (NTM), only 20% of Mycobacterium chelonae and <5% of M. abscessus are susceptible. GAR-936, a novel glycylcycline derivative of minocycline currently in phase II trials, has not been studied against these organisms. METHODS: We compared the in vitro activity of GAR-936 with tetracycline, doxycycline and minocycline by broth microdilution against 73 isolates of RGM and 31 isolates of slowly growing NTM. The RGM included 20 isolates of M. abscessus (18 tetracycline resistant), 26 isolates of M. chelonae (22 tetracycline resistant), and 26 isolates of M. fortuitum group (10 tetracycline resistant). The slowly growing NTM belonged to 5 species and included M. avium complex (9), M. kansasii (5), M. marinum (5), and M. lentiflavum (10). RESULTS: Using a resistance breakpoint of >4 microg/mL for GAR-936 and >8 microg/mL for tetracycline, all RGM were highly susceptible to GAR-936 with an MIC[50] of
Publication Types:
Keywords:
- CL 331002
- Doxycycline
- In Vitro
- Microbial Sensitivity Tests
- Minocycline
- Mycobacterium
- Mycobacterium Infections
- Mycobacterium chelonae
- Tetracycline
- Tetracycline Resistance
- Tetracyclines
- tigecycline
Other ID:
UI: 102269196
From Meeting Abstracts